Mallinckrodt (MNK) Receives $32.80 Consensus Target Price from Analysts

Mallinckrodt (NYSE:MNK) has earned an average rating of “Hold” from the twenty brokerages that are presently covering the firm, Marketbeat reports. Three investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and six have assigned a buy rating to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $32.80.

A number of equities research analysts have recently commented on the company. Cantor Fitzgerald set a $42.00 target price on Mallinckrodt and gave the company a “buy” rating in a research report on Monday, April 2nd. ValuEngine cut Mallinckrodt from a “hold” rating to a “sell” rating in a report on Monday, April 2nd. Wells Fargo set a $18.00 price objective on Mallinckrodt and gave the stock a “hold” rating in a report on Friday, March 16th. Mizuho reiterated a “neutral” rating and issued a $16.00 price objective (down from $21.00) on shares of Mallinckrodt in a report on Friday, March 9th. Finally, Canaccord Genuity set a $20.00 price objective on Mallinckrodt and gave the stock a “hold” rating in a report on Tuesday, March 6th.

How to Become a New Pot Stock Millionaire

Shares of NYSE:MNK traded up $0.42 during trading on Thursday, reaching $14.99. 1,177,458 shares of the company’s stock traded hands, compared to its average volume of 3,772,227. Mallinckrodt has a fifty-two week low of $13.64 and a fifty-two week high of $49.12. The company has a quick ratio of 1.85, a current ratio of 2.18 and a debt-to-equity ratio of 0.98. The stock has a market capitalization of $1,250.35, a PE ratio of 2.00, a price-to-earnings-growth ratio of 0.36 and a beta of 1.12.

Mallinckrodt (NYSE:MNK) last posted its earnings results on Tuesday, February 27th. The company reported $2.01 EPS for the quarter, beating the Zacks’ consensus estimate of $1.72 by $0.29. Mallinckrodt had a return on equity of 13.43% and a net margin of 66.25%. The firm had revenue of $792.30 million for the quarter, compared to analysts’ expectations of $769.91 million. During the same period last year, the firm earned $1.91 EPS. The company’s quarterly revenue was down 4.5% on a year-over-year basis. sell-side analysts expect that Mallinckrodt will post 6.2 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Macquarie Group Ltd. lifted its stake in Mallinckrodt by 62.7% in the 4th quarter. Macquarie Group Ltd. now owns 58,422 shares of the company’s stock worth $9,069,000 after purchasing an additional 22,507 shares in the last quarter. LPL Financial LLC purchased a new stake in shares of Mallinckrodt during the 4th quarter valued at approximately $1,718,000. Sciencast Management LP purchased a new stake in shares of Mallinckrodt during the 4th quarter valued at approximately $210,000. Two Sigma Investments LP purchased a new stake in shares of Mallinckrodt during the 4th quarter valued at approximately $30,841,000. Finally, Two Sigma Advisers LP purchased a new stake in shares of Mallinckrodt during the 4th quarter valued at approximately $24,007,000. 97.38% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “Mallinckrodt (MNK) Receives $32.80 Consensus Target Price from Analysts” was originally posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this article on another site, it was illegally copied and republished in violation of United States & international copyright laws. The correct version of this article can be read at https://ledgergazette.com/2018/04/17/mallinckrodt-mnk-receives-32-80-consensus-target-price-from-analysts.html.

About Mallinckrodt

Mallinckrodt public limited company develops, manufactures, markets, and distributes branded pharmaceutical products in Canada and the European Union, as well as in Latin American, the Middle Eastern, African, and the Asia-Pacific regions. The company markets branded pharmaceutical products for autoimmune and rare diseases in the specialty areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products.

Analyst Recommendations for Mallinckrodt (NYSE:MNK)

Receive News & Ratings for Mallinckrodt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply